ST吉药(300108) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥118,015,687.61, a decrease of 28.59% compared to ¥165,254,931.72 in the same period last year[4] - The net profit attributable to shareholders was -¥52,149,950.90, representing a decline of 51.88% from -¥34,336,148.03 year-on-year[4] - Basic and diluted earnings per share were both -¥0.0783, a decrease of 51.74% compared to -¥0.0516 in the same period last year[4] - Total operating revenue for the first quarter was ¥118,015,687.61, a decrease of 28.5% compared to ¥165,254,931.72 in the previous period[25] - The net loss for the quarter was ¥52,275,394.38, compared to a net loss of ¥35,478,050.15 in the same period last year, indicating a worsening of 47.2%[28] - The operating profit (loss) was reported at -¥45,639,354.14, compared to -¥34,548,937.69 in the previous year[25] Cash Flow - The net cash flow from operating activities was ¥3,897,872.36, down 80.59% from ¥20,078,180.87 in the previous year[4] - Cash inflows from operating activities totaled ¥91,580,873.55, down from ¥147,564,850.90, a decline of 38.0%[32] - The total cash outflow from operating activities amounted to ¥87,683,001.19, down from ¥127,486,670.03, indicating a reduction of 31.2%[34] - Cash received from sales of goods and services was ¥77,852,688.53, down 35% from ¥118,931,499.72 in the same period last year[8] - Cash and cash equivalents decreased to CNY 13,032,765.01 from CNY 25,653,885.94, representing a decline of about 49.1%[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,406,468,647.56, a slight decrease of 0.34% from ¥2,414,668,261.93 at the end of the previous year[4] - The total liabilities increased to ¥2,909,474,302.52 from ¥2,865,398,522.51, reflecting a rise of 1.5%[24] - The equity attributable to shareholders was -¥475,753,055.59, a decrease of 12.31% from -¥423,603,104.69 at the end of the previous year[4] - Current assets totaled CNY 655,508,655.18, compared to CNY 646,447,197.41 at the beginning of the year, indicating a growth of approximately 1.64%[22] Expenses - The company reported a significant increase of 1413% in non-operating expenses, totaling ¥4,587,516.92, primarily due to penalties related to overdue financing leases and entrusted loans[8] - Total operating costs decreased to ¥163,961,790.14 from ¥200,148,795.52, reflecting a reduction of 18.0%[25] - The company reported a financial expense of ¥37,711,830.27, which increased from ¥30,427,505.34, marking a rise of 23.5%[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 62,271[11] - The company reported a total of 183,183,563 restricted shares, with 64,842,560 shares released during the period[16] Research and Development - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the provided content[19] Audit and Reporting - The company did not conduct an audit for the first quarter report[37] - The report was released on June 28, 2022, indicating the company's commitment to timely financial disclosures[37]